z-logo
HomeZAIABlog
open-access-imgOpen Access
Demystifying Zyprexa Relprevv usage
Author(s) -
Tiffany-Jade Kreys
Publication year - 2011
Publication title -
mental health clinician
Language(s) - English
Resource type - Journals
ISSN - 2168-9709
DOI - 10.9740/mhc.n89498
Subject(s) - olanzapine , sedation , medicine , delirium , schizophrenia (object oriented programming) , intensive care medicine , psychiatry , anesthesia
Zyprexa Relprevv, an extended-release injectable suspension of olanzapine, received FDA approval in December 2009 for the treatment of schizophrenia in adults. Due to the risk of post-injection delirium/sedation syndrome (PDSS) associated with Zyprexa Relprevv usage, the injection is only available through a restricted distribution program. This article reviews the impact of PDSS on the use of Zyprexa Relprevv.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

AboutCareersPublisher PartnersContact UsGet Organisational Trial or Quote

Learn

FAQsBlogTerms of UsePrivacy Policy

Download the Zendy App

Get it on
Google Play
Download on the
App Store

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.